<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Urol</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Urol</journal-id>
      <journal-title-group>
        <journal-title>BMC Urology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2490</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">22436420</article-id>
      <article-id pub-id-type="pmc">3348004</article-id>
      <article-id pub-id-type="publisher-id">1471-2490-12-7</article-id>
      <article-id pub-id-type="doi">10.1186/1471-2490-12-7</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Severe paraneoplastic hypereosinophilia in metastatic renal cell carcinoma</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="A1">
          <name>
            <surname>Todenh&#xF6;fer</surname>
            <given-names>Tilman</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>tilman.todenhoefer@med.uni-tuebingen.de</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Wirths</surname>
            <given-names>Stefan</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>stefan.wirths@med.uni-tuebingen.de</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>von Weyhern</surname>
            <given-names>Claus Hann</given-names>
          </name>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>c.vonweyhern@med.uni-tuebingen.de</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Heckl</surname>
            <given-names>Stefan</given-names>
          </name>
          <xref ref-type="aff" rid="I4">4</xref>
          <email>stefan.heckl@med.uni-tuebingen.de</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>Horger</surname>
            <given-names>Marius</given-names>
          </name>
          <xref ref-type="aff" rid="I5">5</xref>
          <email>marius.horger@med.uni-tuebingen.de</email>
        </contrib>
        <contrib contrib-type="author" id="A6">
          <name>
            <surname>Hennenlotter</surname>
            <given-names>Joerg</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>joerg.hennenlotter@med.uni-tuebingen.de</email>
        </contrib>
        <contrib contrib-type="author" id="A7">
          <name>
            <surname>Stenzl</surname>
            <given-names>Arnulf</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>arnulf.stenzl@med.uni-tuebingen.de</email>
        </contrib>
        <contrib contrib-type="author" id="A8">
          <name>
            <surname>Kanz</surname>
            <given-names>Lothar</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>lothar.kanz@med.uni-tuebingen.de</email>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="A9">
          <name>
            <surname>Schwentner</surname>
            <given-names>Christian</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I6">6</xref>
          <email>christian.schwentner@med.uni-tuebingen.de</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Urology, University Hospital Tuebingen, Tuebingen, Germany</aff>
      <aff id="I2"><label>2</label>Department of Internal Medicine, Oncology, Hematology, University Hospital Tuebingen, Tuebingen, Germany</aff>
      <aff id="I3"><label>3</label>Department of Pathology, University Hospital Tuebingen, Tuebingen, Germany</aff>
      <aff id="I4"><label>4</label>Department of Neuroradiology, University Hospital Tuebingen, Tuebingen, Germany</aff>
      <aff id="I5"><label>5</label>Department of Radiology, University Hospital Tuebingen, Tuebingen, Germany</aff>
      <aff id="I6"><label>6</label>Department of Urology, Eberhard-Karls University, Hoppe-Seyler Strasse 3, D-72076 T&#xFC;bingen, Germany</aff>
      <pub-date pub-type="collection">
        <year>2012</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>21</day>
        <month>3</month>
        <year>2012</year>
      </pub-date>
      <volume>12</volume>
      <fpage>7</fpage>
      <lpage>7</lpage>
      <history>
        <date date-type="received">
          <day>7</day>
          <month>11</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>21</day>
          <month>3</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9;2012 Todenh&#xF6;fer et al; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2012</copyright-year>
        <copyright-holder>Todenh&#xF6;fer et al; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.biomedcentral.com/1471-2490/12/7"/>
      <abstract>
        <sec>
          <title>Background</title>
          <p>Renal cell carcinoma can cause various paraneoplastic syndromes including metabolic and hematologic disturbances. Paraneoplastic hypereosinophilia has been reported in a variety of hematologic and solid tumors. We present the first case in the literature of severe paraneoplastic hypereosinophilia in a patient with renal cell carcinoma.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>A 46 year-old patient patient with a history of significant weight loss, reduced general state of health and coughing underwent radical nephrectomy for metastasized renal cell carcinoma. Three weeks after surgery, the patient presented with excessive peripheral hypereosinophilia leading to profound neurological symptoms due to cerebral microinfarction. Systemic treatment with prednisolone, hydroxyurea, vincristine, cytarabine, temsirolimus and sunitinib led to reduction of peripheral eosinophils but could not prevent rapid disease progression of the patient. At time of severe leukocytosis, a considerable increase of cytokines associated with hypereosinophilia was measurable.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>Paraneoplastic hypereosinophilia in patients with renal cell carcinoma might indicate poor prognosis and rapid disease progression. Myelosuppressive therapy is required in symptomatic patients.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>Paraneoplastic</kwd>
        <kwd>Hypereosinophilia</kwd>
        <kwd>Leukocytosis</kwd>
        <kwd>Renal cell carcinoma</kwd>
        <kwd>Leukemoid reaction</kwd>
        <kwd>Encephalopathy</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Renal cell carcinoma can cause various paraneoplastic syndromes such as hypercalcemia, hypertension and ectopic hormone production [<xref ref-type="bibr" rid="B1">1</xref>]. Renal cell carcinoma can also provoke hematologic disturbances such as polycythemia due to an increased production of erythropoietin [<xref ref-type="bibr" rid="B2">2</xref>]. Hypereosinophilia has been reported as a paraneoplastic syndrome in several solid and hematological malignancies. We report the first case of severe paraneoplastic hypereosinophilia with cerebral infarction in a patient with metastatic renal cell carcinoma.</p>
    </sec>
    <sec>
      <title>Case Presentation</title>
      <sec>
        <title>Case presentation and management</title>
        <p>A 46 year-old patient with no relevant diseases in past medical history had a history of significant weight loss, reduced general state of health and coughing. A whole body CT revealed a hypervascularized renal tumor with a level I tumor thrombus [<xref ref-type="bibr" rid="B3">3</xref>] (Figure <xref ref-type="fig" rid="F1">1</xref>) and multiple pulmonary lesions. At the time of primary diagnosis, blood analysis showed a WBC of 19,550/&#x3BC;l (4,000-7,000/&#x3BC;l) with 16% (0-6%) of eosinophilic granulocytes. The patient was admitted to our hospital 7 days after primary diagnosis (day 7) for radical nephrectomy, partial hepatectomy and reconstruction of the inferior vena cava. The intra- and postoperative course was uneventful. Histological examination showed clear cell renal cell carcinoma with sarcomatoid components (Tumor stage: pT4, pNx, M1, L0, V1, Rx, G3). According the MSKCC criteria, the patient was intermediate risk at time of diagnosis [<xref ref-type="bibr" rid="B4">4</xref>]. In an intersciplinary tumor board, the patient was recommended to begin with oral sunitinib. The patient was discharged from hospital 7 days after surgery (day 14) with a WBC of 14,360/&#x3BC;l. On day 29 the patient again presented at our hospital in a reduced general condition, with fever of 38.4&#xB0;C, tachycardia. Laboratory examination demonstrated leukocytosis of 37 &#xD7; 10<sup>3</sup>/&#x3BC;l with 34.2% of eosinophilic granulocytes. Ultrasound revealed a partially liquid mass with 10 &#xD7; 5 cm of size, which was suspicious of abscess formation, confirmed by computed tomography. The liquid mass was subsequently drained and 700 mL of serous fluid could be evacuated. Cultures of the fluid remained sterile. The patient was treated with intravenous antibiotics (vancomycine, tazobactam/piperacilline, and ciprofloxacin). However, leukocytes and eosinophilic granulocytes increased further despite antibiotic therapy and drainage.</p>
        <fig id="F1" position="float">
          <label>Figure 1</label>
          <caption>
            <p><bold>Preoperative imaging showing a hypervascularized renal tumor with a level I tumor thrombus in the vena cava</bold>.</p>
          </caption>
          <graphic xlink:href="1471-2490-12-7-1"/>
        </fig>
        <p>On day 33, the patient presented with a weakness of the left arm. Multiple fresh embolic lesions were detected by MRI (magnetic resonance tomography) in the parietal, temporal and occipital lobes bilaterally (Figure <xref ref-type="fig" rid="F2">2</xref>). Furthermore a small infarction was detected in the cerebellum which led to the suspicion of cardiac emboli. Transthoracal echocardiography showed a profoundly decreased function of the left ventricle with inferior hypokinesia, a low-grade mitral valve insufficiency and no evidence of structures characteristic for endocarditis. The corresponding electrocardiogram showed a sinus tachycardia with ventricular extrasystoles (Lown classification 2). Ultrasound of extracranial vessels did not show significant stenosis. As at this point leukocytes had further increased up to 57,390/&#x3BC;l with 37.7% of eosinophilic granulocytes (Figures <xref ref-type="fig" rid="F3">3</xref> and <xref ref-type="fig" rid="F4">4</xref>).</p>
        <fig id="F2" position="float">
          <label>Figure 2</label>
          <caption>
            <p><bold>A: axial FLAIR image shows multifocal cortical and subcortical hyperintense lesions (arrows) presumed to be of embolic origin</bold>. B and 2 C: axial diffusion-weighted image-DWI (b-value, 1,000 s/mm<sup>2</sup>) (Figure 2B) and corresponding apparent diffusion coefficient (ADC) map demonstrate marked water diffusion restriction in acute embolic ischemia (arrows). Note the drop in signal intensity on ADC-map (Figure 2C, arrows).</p>
          </caption>
          <graphic xlink:href="1471-2490-12-7-2"/>
        </fig>
        <fig id="F3" position="float">
          <label>Figure 3</label>
          <caption>
            <p><bold>Leukocytes and eosinophilic granulocytes count</bold>. Lower bars show doses of applicated drugs.</p>
          </caption>
          <graphic xlink:href="1471-2490-12-7-3"/>
        </fig>
        <fig id="F4" position="float">
          <label>Figure 4</label>
          <caption>
            <p><bold>Peripheral blood smear hypereosinophilia with hypersegmented forms</bold>.</p>
          </caption>
          <graphic xlink:href="1471-2490-12-7-4"/>
        </fig>
        <p>Several tests were performed to rule out non-cancer causes of hypereosinophilia such as parasitic infections, allergy (including determination of serum mast cell tryptase), hypereosinophilic syndrome due to FIP1L1/PDGFR receptor mutations and aberrant lymphocytes (no CD4-positive CD3-negative lymphocytes characteristic for lymphoproliferative hypereosinophilic syndrome), which remained all negative. Consequently, the patient was submitted to the department of medical oncology and received steroids and cytoreductive therapy with hydroxyurea. Doses of hydroxyurea and prednisone were increased stepwise up to 3 g/day and 100 mg/day, respectively. Moreover, the patient received vincristine once (2 mg) and 2 doses of cytarabine (2 &#xD7; 150 mg/24 h) as cytoreductive therapy of symptomatic hypereosinophilia (Figure <xref ref-type="fig" rid="F3">3</xref>).</p>
        <p>A CT performed 2 weeks after the drainage of the fluid collection showed a massive progression of the retroperitoneal tumor mass in the surgical bed (Figure <xref ref-type="fig" rid="F5">5</xref>). Progress of the pleural and pulmonary metastases could be observed as well. Systemic therapy with temsirolimus (25 mg/once a week) was initiated, as at this point, swallowing difficulties (leading to parental nutrition) did not permit oral therapy with sunitinib. This led to a short-term response of pulmonary and pleural manifestations (according to RECIST). The retroperitoneal tumor mass also responded to temsirolimus with tumor necrosis. However, a CT performed one month after initiation of temsirolimus therapy revealed a progressive disease of local relapse with hepatic, pancreatic and diaphragmatic invasion.</p>
        <fig id="F5" position="float">
          <label>Figure 5</label>
          <caption>
            <p><bold>Progression of retroperitoneal tumor mass after radical nephrectomy within 4 weeks (coronal CT-images)</bold>.</p>
          </caption>
          <graphic xlink:href="1471-2490-12-7-5"/>
        </fig>
        <p>Administration of antiproliferative drugs for treatment of hypereosinophilia (cytarabine, hydroxyurea and vincristin) and renal cell carcinoma led to significant reduction of leukocytes and eosinophils as well as pancytopenia (Figure <xref ref-type="fig" rid="F3">3</xref>).</p>
        <p>We performed a multiplex cytokine assay based on Luminex<sup>R </sup>technology (Progen<sup>R</sup>) to determine levels of multiple cytokines of serums drawn on day 44 (&gt; 200.000 leukocytes/&#x3BC;l) and day 74 (8,580 leukocytes/&#x3BC;l). On day 44, we found severely increased concentrations of multiple cytokines and their receptors including bFGF, G-CSF, GM-CSF, HGF, IL2-RA, MCP-1 and MIP-1b. Results are shown in Table <xref ref-type="table" rid="T1">1</xref>.</p>
        <table-wrap id="T1" position="float">
          <label>Table 1</label>
          <caption>
            <p>Levels of multiple cytokines at time of excessive leukocytosis (day 44) and after administration of cytoreductive drugs) (day 74) measured by ultiplex cytokine testing (Progen)</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th align="left">Cytokine</th>
                <th align="left">Unit</th>
                <th align="left">Reference</th>
                <th align="left">Day 44</th>
                <th align="left">Day 74</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left">EGF</td>
                <td align="left">pg/ml</td>
                <td align="left">-780</td>
                <td align="left">201</td>
                <td align="left">15,8</td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">Eotaxin</td>
                <td align="left">pg/ml</td>
                <td align="left">175.8 &#xB1; 49.3</td>
                <td align="left">20,4</td>
                <td align="left">11,6</td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">
                  <bold>FGF-Basic</bold>
                </td>
                <td align="left">pg/ml</td>
                <td align="left">1,5-6,0</td>
                <td align="left">
                  <bold>40,8</bold>
                </td>
                <td align="left">
                  <bold>23,5</bold>
                </td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">
                  <bold>G-CSF</bold>
                </td>
                <td align="left">pg/ml</td>
                <td align="left">27.34 &#xB1; 8.00</td>
                <td align="left">
                  <bold>93,5</bold>
                </td>
                <td align="left">
                  <bold>&lt; LOW &gt;</bold>
                </td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">
                  <bold>GM-CSF</bold>
                </td>
                <td align="left">pg/ml</td>
                <td align="left">-2,3</td>
                <td align="left">
                  <bold>40,6</bold>
                </td>
                <td align="left">
                  <bold>19,8</bold>
                </td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">
                  <bold>HGF</bold>
                </td>
                <td align="left">pg/ml</td>
                <td align="left">120 &#xB1; 120</td>
                <td align="left">
                  <bold>&lt; HIGH &gt;</bold>
                </td>
                <td align="left">
                  <bold>4480</bold>
                </td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">IFN-a</td>
                <td align="left">pg/ml</td>
                <td align="left">16.8 &#xB1; 6.59</td>
                <td align="left">25,3</td>
                <td align="left">&lt; LOW &gt;</td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">IFNy</td>
                <td align="left">pg/ml</td>
                <td/>
                <td align="left">&lt; LOW &gt;</td>
                <td align="left">&lt; LOW &gt;</td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">IL-10</td>
                <td align="left">pg/ml</td>
                <td align="left">9.2 &#xB1; 1.5</td>
                <td align="left">19,3</td>
                <td align="left">15,8</td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">IL-12 p40/p70</td>
                <td align="left">pg/ml</td>
                <td align="left">171.1 &#xB1; 6,25</td>
                <td align="left">104</td>
                <td align="left">52,6</td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">IL-13</td>
                <td align="left">pg/ml</td>
                <td align="left">25.5 &#xB1; 2.94</td>
                <td align="left">35,7</td>
                <td align="left">&lt; LOW &gt;</td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">IL-15</td>
                <td align="left">pg/ml</td>
                <td align="left">16.2 &#xB1; 4.0</td>
                <td align="left">&lt; LOW &gt;</td>
                <td align="left">45,2</td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">IL-17</td>
                <td align="left">pg/ml</td>
                <td align="left">0-127</td>
                <td align="left">28,8</td>
                <td align="left">23,6</td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">IL-1b</td>
                <td align="left">pg/ml</td>
                <td align="left">40.2 &#xB1; 8.78</td>
                <td align="left">25,7</td>
                <td align="left">12,5</td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">
                  <bold>IL-1RA</bold>
                </td>
                <td align="left">pg/ml</td>
                <td align="left">189 &#xB1; 22</td>
                <td align="left">
                  <bold>979</bold>
                </td>
                <td align="left">
                  <bold>241</bold>
                </td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">IL-2</td>
                <td align="left">pg/ml</td>
                <td align="left">2.4 &#xB1; 0.8</td>
                <td align="left">9,16</td>
                <td align="left">6,01</td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">
                  <bold>IL-2R</bold>
                </td>
                <td align="left">pg/ml</td>
                <td align="left">426.5 &#xB1; 22.4</td>
                <td align="left">
                  <bold>12300</bold>
                </td>
                <td align="left">
                  <bold>18300</bold>
                </td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">
                  <bold>IL-4</bold>
                </td>
                <td align="left">pg/ml</td>
                <td align="left">3.34 &#xB1; 0.84</td>
                <td align="left">
                  <bold>35,8</bold>
                </td>
                <td align="left">
                  <bold>&lt; LOW &gt;</bold>
                </td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">IL-5</td>
                <td align="left">pg/ml</td>
                <td/>
                <td align="left">&lt; LOW &gt;</td>
                <td align="left">&lt; LOW &gt;</td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">
                  <bold>IL-6</bold>
                </td>
                <td align="left">pg/ml</td>
                <td align="left">22.8 &#xB1; 7</td>
                <td align="left">
                  <bold>330</bold>
                </td>
                <td align="left">
                  <bold>299</bold>
                </td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">IL-7</td>
                <td align="left">pg/ml</td>
                <td/>
                <td align="left">66,4</td>
                <td align="left">47</td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">
                  <bold>IL-8</bold>
                </td>
                <td align="left">pg/ml</td>
                <td align="left">9.56 &#xB1; 0.4</td>
                <td align="left">
                  <bold>652</bold>
                </td>
                <td align="left">
                  <bold>111</bold>
                </td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">
                  <bold>IP-10</bold>
                </td>
                <td align="left">pg/ml</td>
                <td align="left">4.5-27.1</td>
                <td align="left">
                  <bold>73,6</bold>
                </td>
                <td align="left">
                  <bold>27,3</bold>
                </td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">
                  <bold>MCP-1</bold>
                </td>
                <td align="left">pg/ml</td>
                <td align="left">173.2 &#xB1; 15.04</td>
                <td align="left">
                  <bold>1110</bold>
                </td>
                <td align="left">
                  <bold>377</bold>
                </td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">MIG</td>
                <td align="left">pg/ml</td>
                <td align="left">22.1-52.4</td>
                <td align="left">&lt; LOW &gt;</td>
                <td align="left">&lt; LOW &gt;</td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">MIP-1a</td>
                <td align="left">pg/ml</td>
                <td align="left">88.1 &#xB1; 14.31</td>
                <td align="left">179</td>
                <td align="left">45,8</td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">
                  <bold>MIP-1b</bold>
                </td>
                <td align="left">pg/ml</td>
                <td align="left">135.1 &#xB1; 29.22</td>
                <td align="left">
                  <bold>2640</bold>
                </td>
                <td align="left">
                  <bold>278</bold>
                </td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">RANTES</td>
                <td align="left">pg/ml</td>
                <td align="left">1100-4360</td>
                <td align="left">3750</td>
                <td align="left">664</td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">TNFa</td>
                <td align="left">pg/ml</td>
                <td align="left">34.32 &#xB1; 11.46</td>
                <td align="left">9,21</td>
                <td align="left">5,81</td>
              </tr>
              <tr>
                <td colspan="5">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">VEGF</td>
                <td align="left">pg/ml</td>
                <td align="left">76.6 &#xB1; 6.07</td>
                <td align="left">65,5</td>
                <td align="left">24,1</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <p>Low = concentration below detection limit, High = above detection limit. Reference values were obtained from [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>]</p>
          </table-wrap-foot>
        </table-wrap>
        <p>As swallowing difficulties disappeared, according to his will the patient was set on sunitinib 50 mg/d two months after nephrectomy. The patient could be discharged from hospital in reduced general condition 11 weeks after nephrectomy. Due to further disease progression, the patient died 4 months after primary diagnosis.</p>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>Hypereosinophilia is most commonly associated with allergy and parasitic infections. Furthermore, several drugs, pulmonary and gastrointestinal diseases have been identified as important causes for hypereosinophilia [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>]. Within recent years, a couple of molecular alterations have been identified to account for malignant hypereosinophilic syndromes including rearrangements of the PDGFR receptor [<xref ref-type="bibr" rid="B8">8</xref>]. A mild to moderate increase (&gt; 500/&#x3BC;l to &lt; 1,500/&#x3BC;l) of eosinophils can be found in up to 5% of patients with malignancies [<xref ref-type="bibr" rid="B10">10</xref>]. Severe peripheral hypereosinophilia (&gt; 5,000/&#x3BC;l) has been described in a variety of hematologic and solid tumors including gastrointestinal tumors [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>], bronchial carcinoma [<xref ref-type="bibr" rid="B10">10</xref>], sarcomas [<xref ref-type="bibr" rid="B13">13</xref>] and prostate cancer [<xref ref-type="bibr" rid="B14">14</xref>]. Several cytokines produced by the primary tumor have been identified to account for increased production of eosinophilic granulocytes in the bone marrow including interleukin-3, interleukin-5 and GM-CSF (granulocytes macrophages stimulating factor) [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. Other mechanisms for hypereosinophilia in patients with malignancy include an eosinophilotactic response due to necrosis in the tumor and increased production of eosinophils due to tumor cell dissemination in the bone marrow [<xref ref-type="bibr" rid="B9">9</xref>]. In the case presented here, we found increase of multiple cytokines at the time of massive leukocytosis and hypereosinophilia. G-CSF and GM-CSF which may be secreted by tumor cells and induce production of eosinophils [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>] were significantly elevated. Soluble receptor of interleukin 2 (IL2-RA) has been shown to be an important mediator of autocrine and paracrine regulation of eosinophils [<xref ref-type="bibr" rid="B19">19</xref>]. MIP-1a which is secreted by eosinophils and induces further leukocyte activation was also significantly elevated [<xref ref-type="bibr" rid="B20">20</xref>]. Both, elevation of interleukin 8 and MCP-1, may be explained by TNF-mediated activation of eosinophils [<xref ref-type="bibr" rid="B21">21</xref>]. All these cytokines were significantly lower at time of normal leukocyte count. However, it is not possible to define the exact mechanism of hypereosinophilia in this patient, as the source of the cytokines remained undefined and mediators causing hypereosinophilia may also be induced by eosinophils themselves. The tumor presented with extensive necrotic areas showing massive infiltration of eosinophils (Figure <xref ref-type="fig" rid="F6">6</xref>). Tumor necrosis has been discussed as a factor promoting tumor related hypereosinophila [<xref ref-type="bibr" rid="B22">22</xref>]. However, as a steady increase of leukocytes was observed after resection of the tumor with necrotic areas, tumor necrosis cannot be regarded as the only promoter of increasing eosinophils in the present case and other sources for cytokines promoting hypereosinophilia are probable.</p>
      <fig id="F6" position="float">
        <label>Figure 6</label>
        <caption>
          <p><bold>A and B: Resection specimen of the right kidney and adrenal gland reveals a poorly, in parts sarcomatoid differentiated renal carcinoma</bold>. Gross examination shows infiltration of the adenal gland, renal plevis and macroscopic vascular invasion. A: (H&amp;E, 200&#xD7;) Spindle like shaped tumor cells with small eosiniphilic cytoplasmn and pleomophic nuclei with eosinophilic nucleoli. Interspersed small amounts of histiocytes and small lymphocytes. The amount of eosinophils is not elevated in viable tumor areas. B: (H&amp;E, 400&#xD7;): Areas of tumor necrosis withs rims of histiocytes and increased number of eosinophils.</p>
        </caption>
        <graphic xlink:href="1471-2490-12-7-6"/>
      </fig>
      <p>Paraneolastic eosinophilia is usually mild without any clinical symptoms, but absolute counts may occasionally exceed 25,000/&#x3BC;l and may cause end-organ damage. In a few reported cases of paraneoplastic hypereosinophilia, neurological symptoms occurred due to thromboembolic events with multiple infarctions [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. Significantly reduced left ventricular function in our patient may be interpreted as end-organ damage as well.</p>
      <p>Several studies have shown that paraneoplastic eosinophilia is a poor prognostic sign and indicates metastatic and extensive disease [<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B26">26</xref>]. In a series of 36 cases with paraneoplastic hypereosinophilia, 32 patients had metastatic disease [<xref ref-type="bibr" rid="B27">27</xref>]. The patient reported here had a disseminated disease with pulmonary and bone metastases and presented with extraordinary rapid disease progression with poor response to surgical and systemic treatment. In previously reported cases, peripheral eosinophil count correlated with disease activity [<xref ref-type="bibr" rid="B28">28</xref>]. We could not find a clear correlation between tumor mass and absolute granulocyte count in the reported patient.</p>
      <p>Symptomatic paraneoplastic eosinophilia could be treated with drugs leading to decreased production and function of eosinophilic granulocytes including glucocorticoids, hydroxyurea, vincristine [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>]. Furthermore, reduction of tumor mass either by surgery or systemic treatment has been shown to reduce peripheral eosinophilic counts in paraneoplastic hypereosinophilia [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B28">28</xref>].</p>
      <p>In the present case, a combination of drugs directly targeting function and production of granulocytes (prednisone, hydroxyurea, vincristin, cytarabine) and drugs targeting renal carcinoma (sunitinib and temsirolimus) led to a decrease of absolute leukocytes and eosinophils. Neurologic impairment and general status significantly improved with reduced numbers of eosonophilic granulocytes. First line sunitinib had to be temporarily replaced by temsirolimus, as swallowing difficulties did not permit oral therapy. Temsirolimus led to a short-term response (according to RECIST) 2 weeks after initiation. However, rapid progression was observed only 4 weeks after initiation of systemic therapy. As reduction of prednisone led to significant hypereosinophilia-associated reduction of vigilance with prompt improvement after increase of dosage we consider prednisone as a mainstay of the therapeutic approach. Hence, it leads to reduced eosinophilic count and improvement of hypereosinophilia associated symptoms.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusions</title>
      <p>This is the first reported case in the literature of excessive paraneoplastic hypereosinophilia in a patient with metastatic renal cell carcinoma. Paraneoplastic hypereosinophilia due to renal cell carcinoma might indicate poor prognosis and rapid disease progression. Myelosuppressive therapy is required in symptomatic patients.</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>Written informed consent was obtained from the next of kin of the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors' contributions</title>
      <p>TT was responsible for concept, design, acquisition and interpretation of data. SW contributed to concept, design, acquisition and interpretation of data. CHW was responsible for microscopic and histopathologic elements. SH performed analysis and interpretation of cranial imaging. MH was responsible for radiologic elements and interpretation. JH was responsible for cytokine analysis and interpretation of data. AS contributed to concept and design of the study. LK contributed to concept and design of the study. CS was responsible for acquisition of data, interpretation and critical revision of the manuscript. All authors read and approved the final manuscript.</p>
    </sec>
    <sec>
      <title>Pre-publication history</title>
      <p>The pre-publication history for this paper can be accessed here:</p>
      <p>
        <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2490/12/7/prepub">http://www.biomedcentral.com/1471-2490/12/7/prepub</ext-link>
      </p>
    </sec>
  </body>
  <back>
    <sec>
      <title>Acknowledgements</title>
      <p>None.</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Bedke</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Buse</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kurosch</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Haferkamp</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Jager</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Hohenfellner</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Paraneoplastic syndrome in renal cell carcinoma</article-title>
          <source>Urologe A</source>
          <year>2007</year>
          <volume>46</volume>
          <fpage>45</fpage>
          <lpage>48</lpage>
          <pub-id pub-id-type="doi">10.1007/s00120-006-1269-2</pub-id>
          <pub-id pub-id-type="pmid">17186189</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Da Silva</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Lacombe</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Bruneval</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Casadevall</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Leporrier</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Camilleri</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>Bariety</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Tambourin</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Varet</surname>
            <given-names>B</given-names>
          </name>
          <article-title>Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia</article-title>
          <source>Blood</source>
          <year>1990</year>
          <volume>75</volume>
          <fpage>577</fpage>
          <lpage>582</lpage>
          <pub-id pub-id-type="pmid">2297568</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Moinzadeh</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Libertino</surname>
            <given-names>JA</given-names>
          </name>
          <article-title>Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same?</article-title>
          <source>J Urol</source>
          <year>2004</year>
          <volume>171</volume>
          <fpage>598</fpage>
          <lpage>601</lpage>
          <pub-id pub-id-type="doi">10.1097/01.ju.0000108842.27907.47</pub-id>
          <pub-id pub-id-type="pmid">14713768</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Motzer</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Bacik</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Murphy</surname>
            <given-names>BA</given-names>
          </name>
          <name>
            <surname>Russo</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Mazumdar</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma</article-title>
          <source>J Clin Oncol</source>
          <year>2002</year>
          <volume>20</volume>
          <fpage>289</fpage>
          <lpage>296</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.20.1.289</pub-id>
          <pub-id pub-id-type="pmid">11773181</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Beirne</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Pantelidis</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Charles</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Wells</surname>
            <given-names>AU</given-names>
          </name>
          <name>
            <surname>Abraham</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Denton</surname>
            <given-names>CP</given-names>
          </name>
          <name>
            <surname>Welsh</surname>
            <given-names>KI</given-names>
          </name>
          <name>
            <surname>Shah</surname>
            <given-names>PL</given-names>
          </name>
          <name>
            <surname>du Bois</surname>
            <given-names>RM</given-names>
          </name>
          <name>
            <surname>Kelleher</surname>
            <given-names>P</given-names>
          </name>
          <article-title>Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis</article-title>
          <source>Eur Respir J</source>
          <year>2009</year>
          <volume>34</volume>
          <fpage>1376</fpage>
          <lpage>1382</lpage>
          <pub-id pub-id-type="doi">10.1183/09031936.00028209</pub-id>
          <pub-id pub-id-type="pmid">19541722</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Yurkovetsky</surname>
            <given-names>ZR</given-names>
          </name>
          <name>
            <surname>Kirkwood</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Edington</surname>
            <given-names>HD</given-names>
          </name>
          <name>
            <surname>Marrangoni</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Velikokhatnaya</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Winans</surname>
            <given-names>MT</given-names>
          </name>
          <name>
            <surname>Gorelik</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Lokshin</surname>
            <given-names>AE</given-names>
          </name>
          <article-title>Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b</article-title>
          <source>Clin Cancer Res</source>
          <year>2007</year>
          <volume>13</volume>
          <fpage>2422</fpage>
          <lpage>2428</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-1805</pub-id>
          <pub-id pub-id-type="pmid">17438101</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="other">
          <article-title>Cytokine concentrations in biological fluids</article-title>
          <ext-link ext-link-type="uri" xlink:href="http://www.copewithcytokines.de/cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">http://www.copewithcytokines.de/cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids</ext-link>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Tefferi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Patnaik</surname>
            <given-names>MM</given-names>
          </name>
          <name>
            <surname>Pardanani</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Eosinophilia: secondary, clonal and idiopathic</article-title>
          <source>Br J Haematol</source>
          <year>2006</year>
          <volume>133</volume>
          <fpage>468</fpage>
          <lpage>492</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2141.2006.06038.x</pub-id>
          <pub-id pub-id-type="pmid">16681635</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Rothenberg</surname>
            <given-names>ME</given-names>
          </name>
          <article-title>Eosinophilia</article-title>
          <source>N Engl J Med</source>
          <year>1998</year>
          <volume>338</volume>
          <fpage>1592</fpage>
          <lpage>1600</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM199805283382206</pub-id>
          <pub-id pub-id-type="pmid">9603798</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Manelis</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Aderka</surname>
            <given-names>D</given-names>
          </name>
          <article-title>Eosinophilia associated with malignant tumors of the bronchus and stomach</article-title>
          <source>Harefuah</source>
          <year>1976</year>
          <volume>90</volume>
          <fpage>213</fpage>
          <lpage>215</lpage>
          <pub-id pub-id-type="pmid">1270013</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Balian</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Bonte</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Naveau</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Foussat</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Bouchet-Delbos</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Berrebi</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Vons</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Capron</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Chaput</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Emilie</surname>
            <given-names>D</given-names>
          </name>
          <article-title>Intratumoral production of interleukin-5 leading to paraneoplastic peripheral eosinophilia in hepatocellular carcinoma</article-title>
          <source>J Hepatol</source>
          <year>2001</year>
          <volume>34</volume>
          <fpage>355</fpage>
          <lpage>356</lpage>
          <pub-id pub-id-type="doi">10.1016/S0168-8278(00)00091-X</pub-id>
          <pub-id pub-id-type="pmid">11281573</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Anagnostopoulos</surname>
            <given-names>GK</given-names>
          </name>
          <name>
            <surname>Sakorafas</surname>
            <given-names>GH</given-names>
          </name>
          <name>
            <surname>Kostopoulos</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Margantinis</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Tsiakos</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Terpos</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Pavlakis</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Fortun</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Arvanitidis</surname>
            <given-names>D</given-names>
          </name>
          <article-title>Disseminated colon cancer with severe peripheral blood eosinophilia and elevated serum levels of interleukine-2, interleukine-3, interleukine-5, and GM-CSF</article-title>
          <source>J Surg Oncol</source>
          <year>2005</year>
          <volume>89</volume>
          <fpage>273</fpage>
          <lpage>275</lpage>
          <pub-id pub-id-type="doi">10.1002/jso.20173</pub-id>
          <pub-id pub-id-type="pmid">15726608</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ando</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Sugimoto</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Tamayose</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Ando</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Kojima</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Oshimi</surname>
            <given-names>K</given-names>
          </name>
          <article-title>Cytokine-producing sarcoma mimics eosinophilic leukaemia</article-title>
          <source>Eur J Haematol</source>
          <year>2007</year>
          <volume>78</volume>
          <fpage>169</fpage>
          <lpage>170</lpage>
          <pub-id pub-id-type="pmid">17328718</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Rojas</surname>
            <given-names>GJ</given-names>
          </name>
          <name>
            <surname>Castro</surname>
            <given-names>DM</given-names>
          </name>
          <name>
            <surname>Vigo-Guevara</surname>
            <given-names>GL</given-names>
          </name>
          <name>
            <surname>Ferrua</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Barriga-Maldonado</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Rotta-Escalante</surname>
            <given-names>R</given-names>
          </name>
          <article-title>Hypereosinophilic encephalopathy with multiple cerebral infarctions in neighbouring vascular territories associated with prostate cancer</article-title>
          <source>Rev Neurol</source>
          <year>2006</year>
          <volume>43</volume>
          <fpage>762</fpage>
          <lpage>764</lpage>
          <pub-id pub-id-type="pmid">17160930</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Fridlender</surname>
            <given-names>ZG</given-names>
          </name>
          <name>
            <surname>Simon</surname>
            <given-names>HU</given-names>
          </name>
          <name>
            <surname>Shalit</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Metastatic carcinoma presenting with concomitant eosinophilia and thromboembolism</article-title>
          <source>Am J Med Sci</source>
          <year>2003</year>
          <volume>326</volume>
          <fpage>98</fpage>
          <lpage>101</lpage>
          <pub-id pub-id-type="doi">10.1097/00000441-200308000-00008</pub-id>
          <pub-id pub-id-type="pmid">12920442</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Watanabe</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Ono</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Ozeki</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Tanaka</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Aida</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Okuno</surname>
            <given-names>Y</given-names>
          </name>
          <article-title>Production of granulocyte-macrophage colony-stimulating factor in a patient with metastatic chest wall large cell carcinoma</article-title>
          <source>Jpn J Clin Oncol</source>
          <year>1998</year>
          <volume>28</volume>
          <fpage>559</fpage>
          <lpage>562</lpage>
          <pub-id pub-id-type="doi">10.1093/jjco/28.9.559</pub-id>
          <pub-id pub-id-type="pmid">9793030</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Park</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>ES</given-names>
          </name>
          <name>
            <surname>Noh</surname>
            <given-names>DY</given-names>
          </name>
          <name>
            <surname>Hwang</surname>
            <given-names>KT</given-names>
          </name>
          <name>
            <surname>Moon</surname>
            <given-names>A</given-names>
          </name>
          <article-title>H-Ras-specific upregulation of granulocyte colony-stimulating factor promotes human breast cell invasion via matrix metalloproteinase-2</article-title>
          <source>Cytokine</source>
          <year>2011</year>
          <volume>55</volume>
          <fpage>126</fpage>
          <lpage>133</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cyto.2011.03.002</pub-id>
          <pub-id pub-id-type="pmid">21524920</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Karawajczyk</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Hoglund</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Ericsson</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Venge</surname>
            <given-names>P</given-names>
          </name>
          <article-title>Administration of G-CSF to healthy subjects: the effects on eosinophil counts and mobilization of eosinophil granule proteins</article-title>
          <source>Br J Haematol</source>
          <year>1997</year>
          <volume>96</volume>
          <fpage>259</fpage>
          <lpage>265</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2141.1997.d01-2045.x</pub-id>
          <pub-id pub-id-type="pmid">9029010</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Simon</surname>
            <given-names>HU</given-names>
          </name>
          <name>
            <surname>Plotz</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Simon</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Seitzer</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Braathen</surname>
            <given-names>LR</given-names>
          </name>
          <name>
            <surname>Menz</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Straumann</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Dummer</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Levi-Schaffer</surname>
            <given-names>F</given-names>
          </name>
          <article-title>Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells' syndrome</article-title>
          <source>Eur J Immunol</source>
          <year>2003</year>
          <volume>33</volume>
          <fpage>834</fpage>
          <lpage>839</lpage>
          <pub-id pub-id-type="doi">10.1002/eji.200323727</pub-id>
          <pub-id pub-id-type="pmid">12672048</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Costa</surname>
            <given-names>JJ</given-names>
          </name>
          <name>
            <surname>Matossian</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Resnick</surname>
            <given-names>MB</given-names>
          </name>
          <name>
            <surname>Beil</surname>
            <given-names>WJ</given-names>
          </name>
          <name>
            <surname>Wong</surname>
            <given-names>DT</given-names>
          </name>
          <name>
            <surname>Gordon</surname>
            <given-names>JR</given-names>
          </name>
          <name>
            <surname>Dvorak</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Weller</surname>
            <given-names>PF</given-names>
          </name>
          <name>
            <surname>Galli</surname>
            <given-names>SJ</given-names>
          </name>
          <article-title>Human eosinophils can express the cytokines tumor necrosis factor-alpha and macrophage inflammatory protein-1 alpha</article-title>
          <source>J Clin Invest</source>
          <year>1993</year>
          <volume>91</volume>
          <fpage>2673</fpage>
          <lpage>2684</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI116506</pub-id>
          <pub-id pub-id-type="pmid">8514874</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B21">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Goldstein</surname>
            <given-names>LA</given-names>
          </name>
          <name>
            <surname>Strieter</surname>
            <given-names>RM</given-names>
          </name>
          <name>
            <surname>Evanoff</surname>
            <given-names>HL</given-names>
          </name>
          <name>
            <surname>Kunkel</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>Lukacs</surname>
            <given-names>NW</given-names>
          </name>
          <article-title>TNF-induced IL-8 and MCP-1 production in the eosinophilic cell line, EOL-1</article-title>
          <source>Mediators Inflamm</source>
          <year>1996</year>
          <volume>5</volume>
          <fpage>218</fpage>
          <lpage>223</lpage>
          <pub-id pub-id-type="doi">10.1155/S0962935196000312</pub-id>
          <pub-id pub-id-type="pmid">18475720</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B22">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Lo Re</surname>
            <given-names>V</given-names>
            <suffix>III</suffix>
          </name>
          <name>
            <surname>Fox</surname>
            <given-names>KR</given-names>
          </name>
          <name>
            <surname>Ferrari</surname>
            <given-names>VA</given-names>
          </name>
          <name>
            <surname>Scott</surname>
            <given-names>CH</given-names>
          </name>
          <name>
            <surname>Kossev</surname>
            <given-names>PM</given-names>
          </name>
          <name>
            <surname>Kostman</surname>
            <given-names>JR</given-names>
          </name>
          <article-title>Hypereosinophilia associated with cardiac rhabdomyosarcoma</article-title>
          <source>Am J Hematol</source>
          <year>2003</year>
          <volume>74</volume>
          <fpage>64</fpage>
          <lpage>67</lpage>
          <pub-id pub-id-type="doi">10.1002/ajh.10373</pub-id>
          <pub-id pub-id-type="pmid">12949893</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B23">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Takai</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Sanada</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Hypereosinophilic syndrome evolving to acute lymphoblastic leukemia</article-title>
          <source>Int J Hematol</source>
          <year>1991</year>
          <volume>54</volume>
          <fpage>231</fpage>
          <lpage>239</lpage>
          <pub-id pub-id-type="pmid">1747458</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B24">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Narayanan</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Hussain</surname>
            <given-names>BM</given-names>
          </name>
          <name>
            <surname>Chandralekha</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Sivasankar</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Nair</surname>
            <given-names>MK</given-names>
          </name>
          <article-title>Hypereosinophilic syndrome in acute lymphoblastic leukaemia-case report and literature review</article-title>
          <source>Acta Oncol</source>
          <year>2000</year>
          <volume>39</volume>
          <fpage>241</fpage>
          <lpage>243</lpage>
          <pub-id pub-id-type="doi">10.1080/028418600430860</pub-id>
          <pub-id pub-id-type="pmid">10859020</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B25">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Lowe</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Jorizzo</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Hutt</surname>
            <given-names>MS</given-names>
          </name>
          <article-title>Tumour-associated eosinophilia: a review</article-title>
          <source>J Clin Pathol</source>
          <year>1981</year>
          <volume>34</volume>
          <fpage>1343</fpage>
          <lpage>1348</lpage>
          <pub-id pub-id-type="doi">10.1136/jcp.34.12.1343</pub-id>
          <pub-id pub-id-type="pmid">7035499</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B26">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Chang</surname>
            <given-names>WC</given-names>
          </name>
          <name>
            <surname>Liaw</surname>
            <given-names>CC</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>PN</given-names>
          </name>
          <name>
            <surname>Tsai</surname>
            <given-names>YH</given-names>
          </name>
          <name>
            <surname>Hsueh</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Tumor-associated hypereosinophilia: report of four cases</article-title>
          <source>Changgeng Yi Xue Za Zhi</source>
          <year>1996</year>
          <volume>19</volume>
          <fpage>66</fpage>
          <lpage>70</lpage>
          <pub-id pub-id-type="pmid">8935378</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B27">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Isaacson</surname>
            <given-names>NH</given-names>
          </name>
          <name>
            <surname>Rapoport</surname>
            <given-names>P</given-names>
          </name>
          <article-title>Eosinophilia in malignant tumors; its significance</article-title>
          <source>Ann Intern Med</source>
          <year>1946</year>
          <volume>25</volume>
          <fpage>893</fpage>
          <lpage>902</lpage>
          <pub-id pub-id-type="pmid">20277495</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B28">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Balducci</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Chapman</surname>
            <given-names>SW</given-names>
          </name>
          <name>
            <surname>Little</surname>
            <given-names>DD</given-names>
          </name>
          <name>
            <surname>Hardy</surname>
            <given-names>CL</given-names>
          </name>
          <article-title>Paraneoplastic eosinophilia. Report of a case with in vitro studies of hemopoiesis</article-title>
          <source>Cancer</source>
          <year>1989</year>
          <volume>64</volume>
          <fpage>2250</fpage>
          <lpage>2253</lpage>
          <pub-id pub-id-type="doi">10.1002/1097-0142(19891201)64:11&lt;2250::AID-CNCR2820641111&gt;3.0.CO;2-X</pub-id>
          <pub-id pub-id-type="pmid">2804915</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B29">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Aldebert</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Lamkhioued</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Desaint</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Gounni</surname>
            <given-names>AS</given-names>
          </name>
          <name>
            <surname>Goldman</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Capron</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Prin</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Capron</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Eosinophils express a functional receptor for interferon alpha: inhibitory role of interferon alpha on the release of mediators</article-title>
          <source>Blood</source>
          <year>1996</year>
          <volume>87</volume>
          <fpage>2354</fpage>
          <lpage>2360</lpage>
          <pub-id pub-id-type="pmid">8630398</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B30">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Schleimer</surname>
            <given-names>RP</given-names>
          </name>
          <name>
            <surname>Bochner</surname>
            <given-names>BS</given-names>
          </name>
          <article-title>The effects of glucocorticoids on human eosinophils</article-title>
          <source>J Allergy Clin Immunol</source>
          <year>1994</year>
          <volume>94</volume>
          <fpage>1202</fpage>
          <lpage>1213</lpage>
          <pub-id pub-id-type="doi">10.1016/0091-6749(94)90333-6</pub-id>
          <pub-id pub-id-type="pmid">7798561</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
